Advertisement

Browse Subject Areas

?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

Loading metrics

Open Access

Peer-reviewed

Research Article

The use of ¹⁸F-Fluoro-deoxy-glucose positron emission tomography (¹⁸F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor

Juliana Maynard ,

Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review & editing

* E-mail: Juliana.maynard@alderleyimaging.com

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Cheshire, United Kingdom
⨯
Sally-Ann Emmas,

Roles Formal analysis, Supervision, Writing – original draft

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Cheshire, United Kingdom
⨯
Francois-Xavier Ble,

Roles Formal analysis, Writing – review & editing

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Cheshire, United Kingdom
⨯
Herve Barjat,

Roles Formal analysis, Methodology, Validation

Affiliation Personalised Healthcare & Biomarkers, AstraZeneca, Cheshire, United Kingdom
⨯
Emily Lawrie,

Roles Data curation, Methodology, Resources

Affiliation Drug Safety and Metabolism iMED, AstraZeneca, Cheshire, United Kingdom
⨯
Urs Hancox,

Roles Methodology, Project administration

Affiliation Oncology Imed, Astrazenenca, Cheshire, United Kingdom
⨯
Urszula M. Polanska,

Roles Data curation, Formal analysis, Methodology

Affiliation Oncology Imed, Astrazenenca, Cheshire, United Kingdom
⨯
Alison Pritchard,

Roles Data curation, Methodology

Affiliation Oncology Imed, Astrazenenca, Cheshire, United Kingdom
⨯
Kevin Hudson

Roles Conceptualization, Project administration, Writing – original draft

Affiliation Oncology Imed, Astrazenenca, Cheshire, United Kingdom
⨯

The use of ¹⁸F-Fluoro-deoxy-glucose positron emission tomography (¹⁸F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor

Juliana Maynard,
Sally-Ann Emmas,
Francois-Xavier Ble,
Herve Barjat,
Emily Lawrie,
Urs Hancox,
Urszula M. Polanska,
Alison Pritchard,
Kevin Hudson

x

Published: August 14, 2017
https://doi.org/10.1371/journal.pone.0183048

Reader Comments (0)

Post a new comment on this article

Print

Advertisement

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Biomarkers
Is the Subject Area "Biomarkers" applicable to this article?

Thanks for your feedback.
Pharmacodynamics
Is the Subject Area "Pharmacodynamics" applicable to this article?

Thanks for your feedback.
Positron emission tomography
Is the Subject Area "Positron emission tomography" applicable to this article?

Thanks for your feedback.
Blood sugar
Is the Subject Area "Blood sugar" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Enzyme-linked immunoassays
Is the Subject Area "Enzyme-linked immunoassays" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.